UroGen Pharma (NASDAQ:URGN) Cut to “Neutral” at HC Wainwright
HC Wainwright downgraded shares of UroGen Pharma (NASDAQ:URGN – Free Report) from a buy rating to a neutral rating in a research report released on Thursday, MarketBeat Ratings reports. Several other research firms have also commented on URGN. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research report on Tuesday, April […]
HC Wainwright downgraded shares of UroGen Pharma (NASDAQ:URGN – Free Report) from a buy rating to a neutral rating in a research report released on Thursday, MarketBeat Ratings reports. Several other research firms have also commented on URGN. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research report on Tuesday, April […]
